NL-OMON51301
Not yet recruiting
Not Applicable
Automated speech analysis in psychosis - SPEECH
psychiatrie0 sites25 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- psychiatrie
- Enrollment
- 25
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. All participants must give signed informed consent;
- •2\. Participants have a psychotic disorder classified according to DSM\-5;
- •3\. Participants are 16\-46 years
Exclusion Criteria
- •1\. Unable to give informed consent to all aspects of the study;
- •2\. Unable to speak and be interviewed in Dutch;
- •3\. Neurological comorbidities affecting speech, e.g. brain haemorrhage.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.Study to investigate mitochondrial function and insulin sensitivity in skeletal muscle in subjects with T2DM.Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-003991-27-NLAstraZeneca AB26
Active, not recruiting
Phase 1
COMBIVAS: A trial of rituximab versus rituximab and belimumab for time to remission in ANCA vasculitisANCA-associated vasculitisMedDRA version: 20.1 Level: PT Classification code 10050894 Term: Anti-neutrophil cytoplasmic antibody positive vasculitis System Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-004645-24-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge30
Completed
Not Applicable
Selective mutism - A follow up studyselective mutism - speech deficit10002861NL-OMON34793niversitair Medisch Centrum Utrecht100
Completed
Phase 2
A Phase II/III, Randomized, Single Blinded, Active Controlled Study to Evaluate the Immunogenicity and Safety of inactivated Japanese encephalitis Vaccine in healthy volunteersCTRI/2011/07/001855Bharat Biotech Intl Ltd600
Active, not recruiting
Phase 1
SYMPHONY-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphomaRelapsed/refractory follicular lymphomaMedDRA version: 24.0Level: HLTClassification code 10016903Term: Follicle centre lymphomas, follicular grade I, II, IIISystem Organ Class: 10016903 - Follicle centre lymphomas, follicular grade I, II, IIITherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2019-003333-42-BEEpizyme, Inc; an Ipsen Company568